CDT News & Events

CDT Equity announced it received a notice from Nasdaq indicating it is not in compliance with listing rules due to a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The report was due on May 15. The notice has no immediate effect on the listing or trading of the company's securities. CDT has until July 20 to submit a plan to regain compliance and expects to file its report as soon as the review process is complete.

CDT Equity (CDT) announced that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets. CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for development of AZD5904 in male infertility as discussions continue regarding potential licensing and strategic partnering opportunities. Originally licensed from AstraZeneca (AZN), the company said AZD5904 benefits from an extensive clinical safety package alongside pre-clinical validation in an area of significant unmet medical need and a continually growing market.

CDT Equity (CDT) announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca (AZN), has progressed into the patent cooperation treaty phase. A total of 181 subjects were dosed across five Phase 1 studies. The asset has demonstrated a favorable safety profile, with no overtly drug-related adverse events identified. The company believes this level of human clinical validation, alongside its IP position. The company holds both a composition of matter patent and a method of use patent relating to AZD5904 in idiopathic male infertility, supported by pre-clinical data demonstrating its potential. The progression to PCT stage enables CDT to pursue broader international protection, supporting the potential global development and commercialization of the asset. The company said CDT has identified promising signals for AZD5904 in idiopathic male infertility, as well as in related oncology-associated infertility markets. The company believes these indications represent areas of significant unmet medical need and commercial opportunity. CDT is now actively seeking out-licensing and strategic partnering opportunities to advance AZD5904 into later-stage development.